PEPTIDE T IN HIV-POSITIVE INDIVIDUALS WITH COGNITIVE IMPAIRMENT
Principal Investigator: James Rochon, Ph.D.
Co-Investigator: Raymond P. Bain, Ph.D.
The Peptide T Trial was a double-masked, placebo-controlled, multicenter randomized clinical trial to determine the safety and efficacy of intranasaly administered Peptide T, an octapeptide, on neuropsychological performance in HIV seropositive individuals with cognitive impairment. The 200 randomized participants were followed for a fixed duration of six months of double-blind therapy followed by open-label Peptide T. Secondary clinical measures included motor and sensory neurologic function and laboratory measures of HIV caused immunologic dysfunction.
NIH/NIMH Contract N01-MH10012, 1994-1996.)